ADMA vs PATH
ADMA Biologics Inc (ADMA) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
ADMA Biologics Inc (ADMA) is a biotechnology company listed on US.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported ADMA revenue for 2024-12-31 was $426.5M. Net income was $197.7M. Revenue was up 65.2% from 2023-12-31 to 2024-12-31. ADMA currently screens at market cap $4.39B and trailing P/E 21.9.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
ADMA currently screens at market cap $4.39B and trailing P/E 21.9. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the ADMA and PATH stock pages for the full models.
Not investment advice.